Discontinuation report RAPAFLO
Report ID | 149531 |
Drug Identification Number | 02361671 |
Brand name | RAPAFLO |
Common or Proper name | Silodosin Capsules |
Company Name | ALLERGAN INC |
Market Status | CANCELLED POST MARKET |
Active Ingredient(s) | SILODOSIN |
Strength(s) | 8MG |
Dosage form(s) | CAPSULE |
Route of administration | ORAL ORAL |
Packaging size | HDPE Bottle 90s |
ATC code | G04CA |
ATC description | DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY |
Reason for discontinuation | Business reasons |
Anticipated discontinuation date | 2021-11-17 |
Actual discontinuation date | 2022-10-31 |
Remaining supply date | 2022-10-31 |
Discontinuation status | Discontinued |
Discontinuation decision reversal | No |
Information on remaining supply | |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Company contact information | Company contact information; Telephone number: 800-668-6424 Email address: MR-GENERAL_INQUIRY@allergan.com Website address: allergan.ca Postal address: 500-85 Enterprise Blvd, Markham, Ontario, L6G 0B5 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v11 | 2022-11-14 | French | Compare |
v10 | 2022-11-14 | English | Compare |
v9 | 2022-11-14 | French | Compare |
v8 | 2022-11-14 | English | Compare |
v7 | 2022-11-08 | French | Compare |
v6 | 2022-11-08 | English | Compare |
v5 | 2022-11-08 | English | Compare |
v4 | 2022-03-15 | French | Compare |
v3 | 2022-03-15 | English | Compare |
v2 | 2021-11-17 | French | Compare |
v1 | 2021-11-17 | English | Compare |
Showing 1 to 11 of 11